149353-95-7

Basic information

• Product Name: 2-(TERT-BUTOXYCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-CARBOXYLIC ACID
• Synonyms: 3,4-DIHYDRO-1H-ISOQUINOLINE-2,7-DICARBOXYLIC ACID 2-TERT-BUTYL ESTER;2-(TERT-BUTOXYCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-CARBOXYLIC ACID;N-BOC-7-HYDROXYCARBONYL-1,2,3,4-TETRAHYDROISOQUINOLINE;2-Boc-1,2,3,4-Tetrahydroisoquinoline-7-Carboxylic Acid;N-Boc-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid;7-Isoquinolinecarboxylicacid-N-tertbutylester;2-Boc-1,2,3,4-tetrahydro-...
• CAS NO: 149353-95-7
• Molecular Formula: C₁₅H₁₉NO₄
• Molecular Weight: 277.32
• Product Categories: pharmacetical
• Mol File: 149353-95-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 151-153 °C
• Boiling Point: 429.3 °C at 760 mmHg
• Flash Point: 213.4 °C
• Appearance: /
• Density: 1.221 g/cm³
• Vapor Pressure: 3.93E-08mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: 2-8°C
• PKA: 4.37±0.20(Predicted)
• CAS DataBase Reference: 2-(TERT-BUTOXYCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(TERT-BUTOXYCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-CARBOXYLIC ACID(149353-95-7)
• EPA Substance Registry System: 2-(TERT-BUTOXYCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-CARBOXYLIC ACID(149353-95-7)

Safety Data

• Hazardous Substances Data: 149353-95-7(Hazardous Substances Data)

Usage

General Description

2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid is a synthetic organic compound that belongs to the class of heterocyclic compounds. It is a carboxylic acid derivative with a tert-butoxycarbonyl protecting group, commonly used in organic synthesis to protect amines and enable selective reactions. The compound has potential applications in the pharmaceutical industry as a building block for the synthesis of various biologically active compounds. Its unique structure and functional groups make it a versatile and valuable intermediate for the preparation of pharmaceuticals and other fine chemical products.

InChI:InChI=1/C15H19NO4/c1-15(2,3)20-14(19)16-7-6-10-4-5-11(13(17)18)8-12(10)9-16/h4-5,8H,6-7,9H2,1-3H3,(H,17,18)

Upstream product

• 258515-65-0 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester 
• 14028-67-2 N-acetyl-1,2,3,4-tetrahydroisoquinoline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1160514-72-6 2-acetyl-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid 
• 960305-54-8 2-tert-butyl 7-methyl 3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate 
• 160346-57-6 1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid 

Downstream Products

• 1436426-34-4 tert-butyl 7-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1436422-07-9 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2-(2-(methylsulfonyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide 
• 1436422-17-1 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide 
• 1436422-20-6 2-butyl-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide 
• 1436423-83-4 2-butyryl-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide 

Relevant articles and documents

INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT

The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: Formula (I) wherein R1, R2, R3, R4, R6

ANTIVIRAL COMPOUNDS

This invention relates to a series of tricyclic compounds comprising a pteridinone core linked to a third heterocycloalkyl ring. The compounds are useful in the treatment of Hepatitis B viral infections. The invention also relates to pharmaceutical compos

MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof that are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. The present invention further relates to methods of treatment and alleviation of diseases and disorders of the vasculature resulting from vasoconstriction or hypertension and any downstream complication(s) resulting from elevated blood pressure and/or reduced tissue perfusion.